INM - InMed Pharma says phase 2 trial for skin disorder cannabinol cream can now include teens
- InMed Pharmaceuticals ( NASDAQ: INM ) on Monday said its phase 2 trial with its cannabinol-based cream for the treatment of skin disorder epidermolysis bullosa was recently expanded to include adolescents following a positive recommendation from a data safety board.
- INM stock +5% to $0.40 in premarket trading.
- An independent committee agreed that it would be safe to allow children aged 12 to 17 into InMed's ( INM ) mid-stage trial evaluating INM-755 CBN cream for epidermolysis bullosa.
- The committee's recommendation was based on the safety data of the first five adult patients who completed the mid-stage study.
- The first adult patient was enrolled in Dec. 2021 and, to date, nine patients have been enrolled in the study.
For further details see:
InMed Pharma says phase 2 trial for skin disorder cannabinol cream can now include teens